首創證券(601136.SH):已全面接入DeepSeek-R1 671B 和 DeeepSeek-V3 671B模型
格隆匯3月21日丨首創證券(601136.SH)在互動平台表示,公司持續開展科技創新,積極探索人工智能的應用場景:在客户開户、業務辦理等領域,運用OCR、活體識別等人工智能技術提升業務流程辦理質效,降低操作失誤率;在公司運營管理等領域,公司自2024年初就開始跟進AI在金融行業應用的探索,部署了多個開源大語言模型,目前已全面接入DeepSeek-R1 671B 和 DeeepSeek-V3 671B模型,用於AI編碼、AIOps、知識庫建設及投研領域的智能體開發。公司尚未與杭州深度求索人工智能基礎技術研究有限公司開展商業合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.